Company profile
Medimmune Limited is a UK company with status active founded in 1989 based in East of England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
RESOLUTIONS | Transaction WURHODBFWlZhZGlxemtjeA | Paper/PDF filed
Published 27 Nov 2024 02:32
MA | Transaction MzQ0NDEzNTM1MWFkaXF6a2N4 | Paper/PDF filed
Published 27 Nov 2024 02:31
CH01 | Transaction MzQzMzQ4NjkxOWFkaXF6a2N4
Published 28 Aug 2024 10:29
363A | Transaction MTM3NTAwMjdhZGlxemtjeA | Paper/PDF filed
Published 26 Feb 2025 05:43
Company registered at Companies House
1 Feb 2018 to 31 Oct 2018
"Human Papilloma Virus (HPV) has been implicated in a range of cancers. Currently, a prophylactic vaccine is prescribed for adolescent girls with a view to prevent infection by HPV. However, this preventative vaccine does not have a therapeutic effect on malignancies developed as a result of HPV infection. In this regard, the use of nucleic acid vaccines ...
1 Jun 2015 to 31 Aug 2016
Biopharmaceuticals (or biologics) are medicines that are made from biological materials, most usually proteins. The UK is a promininet stakeholder in this sector, which is growing in importance as biologics are often more specific to their target in the body and have fewer side effects. The development and production of biologics is, however, a labour and...
1 Jun 2014 to 30 Nov 2015
Sphere Fluidics Limited is an SME focusing on the development of novel, single cell analysis technologies. MedImmune, the global biopharmaceuticals arm of AstraZeneca, is a pioneer in biopharmaceutical discovery and development. Both companies have pooled their synergistic, science skills to propose the development of a unique, integrated microfluidic ins...
1 Feb 2014 to 31 Aug 2014
The treatment of some chronic diseases such as rheumatoid arthritis sometimes requires more than a typical tablet or ‘pill’ can deliver. A new generation of so-called ‘biopharmaceutical’ medicines includes substances which cannot be swallowed because they are destroyed in the stomach. These include ‘monoclonal antibodies’, or mAbs, which are injected subc...
1 Oct 2007 to 31 Mar 2012
The cost to patients and healthcare providers for Monoclonal Antibody (MAb) treaments has traditionally been high. The complex process required to generate, purify and formulate the drug add significantly to the overall cost. Although efforts have been made to reduce costs by looking at increasing manufacturing efficiencies e.g., selection of new chromato...
1 May 2006 to 31 Jan 2010
Awaiting Public Summary
